Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib in Pediatric BRAF V600-Mutation Positive Solid Tumors
NCT01677741Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2013
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of dabrafenib + trametinib in low-grade glioma (LGG), glioma, Langerhans cell histiocytosis (LCH), melanoma, Papillary Thyroid Carcinoma (PTC), sponsored by Novartis. Started May 2013; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
low-grade glioma (LGG)gliomaLangerhans cell histiocytosis (LCH)melanomaPapillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT01677741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677741.